Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.58 |
| ▸ | BRD4 | O60885 | 6/20 | 0.57 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL1B | P01584 | 1/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | AXL | P30530 | 2/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17873770 | 1.00 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL17884396 | 1.00 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL31526946 | 1.00 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL31526908 | 1.00 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL17873802 | 0.99 | CRBN (0.59) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL20933080 | 0.96 | CRBN (0.60) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL26323878 | 0.95 | CRBN (0.63) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL26323874 | 0.95 | CRBN (0.63) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL26321035 | 0.95 | CRBN (0.63) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL26317744 | 0.95 | CRBN (0.63) | CRBNBRD4IKZF1TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280044-B2 | Proteolysis-targeting chimera molecule and preparation method and use thereof | GUANGZHOU MEDICAL UNIVERSITY (CN) | 2025-04-22 | — | — | US | disclosed |
| US-20240245671-A1 | PROTEOLYSIS-TARGETING CHIMERA MOLECULE AND PREPARATION METHOD AND USE THEREOF | GUANGZHOU MEDICAL UNIVERSITY (CN) | 2024-07-25 | — | — | US | disclosed |
| WO-2024012021-A1 | PROTAC MOLECULE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 广州医科大学 | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245671-A1 | PROTEOLYSIS-TARGETING CHIMERA MOLECULE AND PREPARATION METHOD AND USE THEREOF | TYR, PSME1, PSMA1 | CRBN 39/4885BRD4 3061/4885IKZF1 1137/4885 |
| US-12280044-B2 | Proteolysis-targeting chimera molecule and preparation method and use thereof | TYR, PSME1, PSMA1 | CRBN 39/4885BRD4 3061/4885IKZF1 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.